Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121567) titled 'A study on the efficacy and safety of risankizumab in the treatment of Crohn's disease' on April 1.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Sixth Affiliated Hospital, Sun Yat-sen University
Condition:
Crohn's disease
Intervention:
Guselkumab Treatment Group (CD Cohort):None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-01
Target Sample Size: Guselkumab Treatment Group (CD Cohort):100;Healthy Control Group (Healthy Control Cohort):30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.htm...